- Company is seeking guidance on development plan of Iomab-B for the EU market
- Actinium’s small and medium-sized (SME) status and orphan designation results in a 100%
reduction in fees for scientific advice
NEW YORK, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the
Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today that the Company has initiated the European Medicines Agency (EMA) Scientific Advice process for Iomab-B.
The EMA provides scientific advice to companies regarding the appropriate studies for the development of a medicine. The goal of
scientific advice is to facilitate the development and availability of high-quality, effective and acceptably safe medicines, for
the benefits of patients.
The Scientific Advice process allows Actinium to dialogue with regulators from the EMA to determine the
appropriate development program for Iomab-B in Europe. The EMA created this program to increase the probability of positive
outcomes and to reduce the risk of objections during the evaluation of a market-authorization application. Iomab-B, Actinium’s lead
drug candidate, has been granted orphan designation in the European Union (EU) by the EMA. Iomab-B is intended to be used, upon
marketing authorization, in preparing patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55
for a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT). Iomab-B is currently in a 150
patient multicenter, pivotal Phase 3 trial that is being conducted in the United States.
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, “We are very excited about the potential of
Iomab-B in Europe to address an urgent unmet medical need. We believe Iomab-B is a potentially revolutionary therapy for
relapsed or refractory AML patients who are over the age of 55 that could benefit from a bone marrow transplant. This remains a
patient population that is drastically underserved on a global scale. Today’s initiation for scientific advice, together with our
SME status and orphan designation for Iomab-B in the EU, is invaluable as we explore the regulatory pathway for Iomab-B in the EU.
We will continue to drive the development of Iomab-B in the U.S. and beyond as we endeavor to bring Iomab-B to all patients that
could potentially benefit from this drug candidate.”
About Iomab-B
Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131
radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely
expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for
hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic
myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin
lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site
of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its
proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta
emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate
Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to
as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory
or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product
candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age
of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause
actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and
actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: Actinium Pharmaceuticals, Inc. Steve O'Loughlin Vice President, Finance and Corporate Development soloughlin@actiniumpharma.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/a8e75acf-d158-4e32-b6a8-6ab4821b54ec?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=MTg0IzY1OTgzODg=)